Publications (3)0 Total impact
-
Article: S182 and STM2 gene missense mutations in sporadic Alzheimer disease
American Journal of Medical Genetics 03/2007; 67(4):429 - 429. -
Article: Evidence that an atypical β-adrenoceptor mediates the prejunctional inhibition of non-adrenergic non-cholinergic contraction in guinea-pig bronchi
[show abstract] [hide abstract]
ABSTRACT: We investigated the effect of the putative β3 agonist BRL 35135 on non-adrenergic non-cholinergic (NANC) contractions in guinea-pig bronchial strips. BRL 35135 (10−9 to 10−6 M) did not alter the baseline tension but reduced NANC contractions induced by electrical field stimulation (EFS) in a concentration-dependent fashion without having a significant effect on the contraction induced by substance P (10−6 M). BRL 35135 (10−6 M) also reduced the contraction induced by capsaicin (10−7 M). Likewise, BRL 37344 (10−9 to 10−6 M) reduced NANC contractions induced by EFS in a concentration-dependent fashion. While BRL 37344 up to concentrations of 10−8 M did not alter the contraction induced by SP (10−6 M), BRL 37344 (10−8 M) significantly inhibited NANC contractions induced by EFS and capsaicin (10−7 M) (P < 0.01). The inhibitory effect of BRL 35135 (10−6 M) on NANC contractions induced by EFS was not significantly altered by the non-selective β-adrenoceptor antagonists, propranolol and pindolol (P > 0.10), by the β1-selective antagonists, atenolol and metoprolol (P > 0.20) (10−8 to 10−6 M), or by the α-adrenoceptor antagonist, phentolamine (10−7 to 10−5 M) (P > 0.50). These results suggest that β3 agonists exert a prejunctional inhibitory action on NANC contractions.European Journal of Pharmacology. -
Article: Absence of Association of α1-Antichymotrypsin Polymorphisms with Alzheimer's Disease: A Report on Autopsy-Confirmed Cases
[show abstract] [hide abstract]
ABSTRACT: α1-Antichymotrypsin (ACT) polymorphisms were examined in 79 cases with autopsy-confirmed Alzheimer's disease (AD) as well as in 28 cases with autopsy-confirmed nonneurological diseases to test the hypothesis that ACT polymorphisms confer a risk to an individual to develop AD. Neither ACT genotype frequency nor ACT allele frequency in the AD group was significantly different from the control group. The ACT polymorphic pattern was essentially the same among apolipoprotein E (apoE) ϵ4 carriers and noncarriers. The age at onset of AD was not significantly affected by the inherited dose of ACT/A allele. Taking together, our observations do not confirm the effect of the ACT/A allele as a risk factor for developing AD in addition to the ApoE ϵ4 allele.Experimental Neurology.
